Hemato Oncology Testing Market

Hemato Oncology Testing Market by Cancer Types (Leukaemia [Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia], Lymphoma [Non-Hodgkin Lymphoma and Hodgkin Lymphoma], Myeloproliferative Neoplasms [Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis], and Others), Technology (PCR [Real-time qPCR and Digital PCR], IHC, NGS, Cytogenetics, and Others), End-users (Hospitals, Academic & Research Institutes, and Others), Products (Assay Kits & Reagents and Services), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1257
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 185
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global hemato oncology testing market is anticipated to expand at a substantial CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the increasing prevalence of lymphoma and myeloma. Rising extensive research projects from key players for the development of innovative and advanced testing devices are key aspects for the market development.
 

Hemato Oncology Testing Market Key Takeaways


Hemato oncology testing involves a wide range of medical tests that focus to identify or detect the presence of blood diseases and cancer and to offer treatment for the same. Some of the most popular types of cancers that hematologists and oncologists are dealing with include leukemia, lymphomas, and myeloproliferative neoplasms, which are identified to be major reasons for tumor formation.

One of the key aspects for the rapid expansion of the oncology testing market is the growing investment from public-private enterprises for the development of several human genome projects especially in developed regions. Moreover, several studies are being extensively conducted for gene sequencing process, diagnostic procedures, and blood cancer to find drug development and develop advanced treatment for cancer patients. In 2017, the European Commission approved the first companion diagnostic device for the diagnosis of Acute Myeloid Leukemia (AML). Furthermore, a trial study was undertaken by a blood cancer research charity team, Blood wise, in 2018 presented certain findings that could help developing right medications for the treatment of AML in the immediate future.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing prevalence of cancer and blood diseases due to inactive lifestyle, excessive consumption of alcohol, and smoking habits are key driving factors for the market growth.
  • Rising demand for advanced gene sequencing activities and personalized medicine are driving the growth of the market.
  • Increasing adoption of innovative molecular techniques for the diagnosis and development of innovative diagnostic devices are projected to push the market expansion.
  • High cost of oncology testing and Lack of skill operators for handling testing especially in developing nations prove to be key challenges that can impede the market growth.
  • Massive R&D activities from key players to improve the testing result and higher accuracy of the diagnosis are offering lucrative opportunities for the market expansion.

Scope of the Report

The report on the global hemato oncology testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Hemato Oncology Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Cancer Types (Leukaemia [Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia], Lymphoma [Non-Hodgkin Lymphoma and Hodgkin Lymphoma], Myeloproliferative Neoplasms [Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis], and Others), Technology (PCR [Real-time qPCR and Digital PCR], IHC, NGS, Cytogenetics, and Others), End-users (Hospitals, Academic & Research Institutes, and Others), and Products (Assay Kits & Reagents and Services)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

F. Hoffman-La Roche Ltd; Abbott Laboratories; EntroGen, Inc.; Qiagen N.V.; Cepheid; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; and Illumina, Inc.

 

Market Segment Insights

Lymphoma segment to hold a large revenue share
Based on cancer types, the global hemato oncology testing market is divided into leukemia, lymphoma, myeloproliferative neoplasms, and others. The leukemia segment is further divided into acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. The lymphoma segment includes non-hodgkin lymphoma (NHL) and hodgkin lymphoma. Meanwhile, the myeloproliferative neoplasms segment consists of polycythemia vera, essential thrombocythemia, and myelofibrosis.

The lymphoma segment is expected to hold a large revenue share during the forecast period owing to wide prevalence of the type of cancer worldwide. According to the National Institutes of Health (NIH), NHL is the seventh most prevalent cancer in the US, accounting for nearly 4.2 percent of all cancers. Similarly, according to Cancer Research UK, the prevalence of NHL has been increasing, with 13,900 new cases diagnosed per year in the United Kingdom. NHL is the sixth most prevalent form of cancer in the country, accounting for 4% of all new cases. Since the early 1990s, the prevalence of NHL in the UK has risen to 39%. As a result, a number of private and public organizations are launching campaigns. The Leukemia Foundation, for example, offers a collection of services to help people become more knowledgeable of blood cancer.

PCR segment to account for a key market share
On the basis of technology, the market is segmented into PCR, IHC, NGS, cytogenetics, and others. The PCR segment consists of real-time qPCR and digital PCR. The PCR segment is projected to account for a key market share in the coming years due to its ease of use, low cost, high accuracy and performance, and widespread availability of the testing technology. Abbott's Real Time IDH1 assay was launched in July 2018 by the Blood Center of Wisconsin's Diagnostic Laboratories. This is a PCR procedure that detects IDH1 genetic mutations in patients' bone marrow and blood samples with high sensitivity. As a result, an increase in the number of PCR-based experiments being launched is expected to propel the market forward during the forecast era.

Hospital segment is leading the market
Based on End-users, the global hemato oncology testing market is divided into hospitals, academic & research institutes, and others. The hospitals segment dominated the market, accounting for about more than 71.5% of total sales in 2020. Factors such as wide availability of the myriad diagnostic testing, availability of advanced laboratory settings, and involvement of high experts and healthcare practitioners to perform diagnostic tests are key factors pushing the segment growth.

Furthermore, owing to the existence of academic groups that perform numerous studies and researches to advance the field of hemato oncology, the academic & research institutes segment is anticipated to constitute a significant share of the market in the coming years. Benefits such as a better understanding of the diagnostic process and the availability of technologically innovative diagnostic devices are expected to propel the segment at a rapid pace.
 

Hemato Oncology Testing Market by End Users


North America to represent a major share
In terms of regions, the market is classified as as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to represent a major share of the market during the forecast period due to wide incidence of leukemia, lymphoma, and multiple myelom. In addition, the regional market is being driven by supporting steps taken by major market players as well as numerous academic & research organizations. Meanwhile, the market in Asia Pacific is anticipated to register a high growth rate owing to an increase in the prevalence of blood cancer and a growing number of research activities conducted by various academic research institutes. For instance, in August 2019, scientists from Monash University developed a novel blood test that could help in the detection of myeloma effectively.
 

Hemato Oncology Testing Market by Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hemato Oncology Testing Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Hemato Oncology Testing Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Hemato Oncology Testing Market - Supply Chain
  4.5. Global Hemato Oncology Testing Market Forecast
     4.5.1. Hemato Oncology Testing Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Hemato Oncology Testing Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Hemato Oncology Testing Market Absolute $ Opportunity
5. Global Hemato Oncology Testing Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Hemato Oncology Testing Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Hemato Oncology Testing Demand Share Forecast, 2019-2026
6. North America Hemato Oncology Testing Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Hemato Oncology Testing Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Hemato Oncology Testing Demand Share Forecast, 2019-2026
7. Latin America Hemato Oncology Testing Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Hemato Oncology Testing Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Hemato Oncology Testing Demand Share Forecast, 2019-2026
8. Europe Hemato Oncology Testing Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Hemato Oncology Testing Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Hemato Oncology Testing Demand Share Forecast, 2019-2026
9. Asia Pacific Hemato Oncology Testing Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Hemato Oncology Testing Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Hemato Oncology Testing Demand Share Forecast, 2019-2026
10. Middle East & Africa Hemato Oncology Testing Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Hemato Oncology Testing Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Hemato Oncology Testing Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Hemato Oncology Testing Market: Market Share Analysis
  11.2. Hemato Oncology Testing Distributors and Customers
  11.3. Hemato Oncology Testing Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. F. Hoffman-La Roche Ltd
     11.4.2. Abbott Laboratories
     11.4.3. EntroGen, Inc.
     11.4.4. Qiagen N.V.
     11.4.5. Cepheid

Segments Covered in the Report
The global hemato oncology testing market has been segmented on the basis of

Cancer Types

  • Leukemia
    • Acute Myeloid Leukemia (AML)
    • Acute Lymphocytic Leukemia (ALL)
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
  • Lymphoma
    • Non-Hodgkin Lymphoma
    • Hodgkin Lymphoma
    • Myeloproliferative Neoplasms
  • Polycythemia Vera (PV)
    • Essential Thrombocythemia (ET)
    • Myelofibrosis (MF)
  • Others

Technology

  • PCR
    • Real-time qPCR
    • Digital PCR
  • IHC
  • NGS
  • Cytogenetics
  • Others

End-users

  • Hospitals
  • Academic & Research Institutes
  • Others

Products

  • Assay Kits & Reagents
  • Services

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • F. Hoffman-La Roche Ltd
  • Abbott Laboratories
  • EntroGen, Inc.
  • Qiagen N.V.
  • Cepheid
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.

Some of the key players competing in the market are F. Hoffman-La Roche Ltd, Abbott Laboratories, EntroGen, Inc., Qiagen N.V., Cepheid, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., and Illumina, Inc. During the forecast period, the market is expected to expand due to an increase in partnerships among various market players. For example, Adaptive Biotechnologies and AbbVie entered into a partnership in December 2019 to use Adaptive's NGS-based minimal residual disease testing in multiple myeloma drug trials.
 

Hemato Oncology Testing Market by Key Players

Buy Report